WHAT TO KEEP IN MIND
Interest is not proof.
All three products remain investigational for many proposed uses, and much of the research is preclinical. TB 500 evidence must remain distinct from the broader thymosin beta 4 literature. GHK CU evidence varies by delivery method and research area. Overlapping research themes do not prove that combining these products produces a better outcome.


